Daily Respiratory Research Analysis
Analyzed 133 papers and selected 3 impactful papers.
Summary
Analyzed 133 papers and selected 3 impactful articles.
Selected Articles
1. A Pumilio-dependent post-transcriptional mechanism drives pulmonary hypertension via KCNK3 suppression.
This mechanistic study identifies hypoxia → HIF1α → PUM2 upregulation that binds KCNK3 mRNA 3'UTR and destabilizes it, reducing KCNK3 protein in PASMCs. PUM2 knockdown restores KCNK3, increases apoptosis, reduces proliferation/migration in vitro, and ameliorates haemodynamics and remodelling in two rat PH models; effects are KCNK3-dependent.
Impact: Uncovers a novel, targetable post-transcriptional regulator (PUM2) of KCNK3 with in vivo therapeutic proof-of-concept in PH models, advancing mechanistic understanding and nominating a new class of targets.
Clinical Implications: Although preclinical, the work nominates PUM2 (and possibly PUM1) as druggable targets to restore KCNK3 function in pulmonary hypertension. This supports development of RNA-targeted therapies (antisense, AAV/shRNA) or small molecules that modulate Pumilio activity as candidate translational approaches.
Key Findings
- Hypoxia induces HIF1α-dependent upregulation of PUM2 in PASMCs and in PH rat lungs.
- PUM2 binds the 3'UTR of KCNK3 mRNA, destabilizing the transcript and lowering KCNK3 protein levels.
- PUM2 knockdown (AAV9 in vivo) rescues KCNK3 expression, increases PASMC apoptosis, reduces proliferation/migration, and ameliorates haemodynamics and vascular remodelling in two rat PH models; effects reversed by KCNK3 knockdown.
Methodological Strengths
- Use of multiple complementary in vivo PH models (Sugen5416/hypoxia and monocrotaline) and human PASMCs for translational relevance.
- Mechanistic validation with genetic perturbation (knockdown and overexpression) and downstream rescue experiments demonstrating KCNK3 dependence.
Limitations
- Therapeutic interventions were preclinical; safety, delivery, and long-term effects of PUM2 targeting in humans remain unknown.
- Potential redundancy with PUM1 raises challenges for single-target strategies; off-target effects of Pumilio modulation were not exhaustively explored.
Future Directions: Next steps should include assessment of PUM2/PUM1 expression in human PH patient tissues, development of clinically tractable Pumilio inhibitors or RNA therapeutics, evaluation of long-term safety and efficacy, and investigation of possible compensatory mechanisms.
Pulmonary hypertension (PH) is a lethal vascular disorder characterized by obstructive remodelling of pulmonary arteries, driven predominantly by pathological phenotypes of pulmonary artery smooth muscle cells (PASMCs), including excessive proliferation, migration, and resistance to apoptosis. While the RNA-binding protein PUM2 and the potassium channel KCNK3 have been implicated in cardiovascular pathophysiology, their functional interplay in hypoxic pulmonary vascular remodelling remains undefined. Here, using rat models of PH (Sugen5416/hypoxia and monocrotaline), human PASMCs, and mechanistic assays, we identify a signalling axis in which hypoxia induces HIF1α-dependent transcriptional upregulation of PUM2. PUM2 in turn binds the 3'UTR of KCNK3 mRNA, destabilizing the transcript and reducing KCNK3 protein expression. Knockdown of PUM2 restored KCNK3 expression, promoted apoptosis, and suppressed proliferation and migration in PASMCs, whereas PUM2 overexpression exerted opposing effects. These phenotypic changes were reversed by concomitant KCNK3 knockdown, confirming KCNK3 as a critical downstream effector. In vivo, AAV9-mediated PUM2 knockdown ameliorated haemodynamic impairment, vascular remodelling, and right ventricular hypertrophy in PH rats, whereas PUM2 overexpression exacerbated disease progression. Notably, the related family member PUM1 exhibited similar hypoxia-induced upregulation and direct binding to KCNK3 mRNA, suggesting potential functional redundancy within the Pumilio family. Collectively, our results unveil a Pumilio-dependent post-transcriptional mechanism as a central driver of PASMC dysfunction in PH and nominate PUM2-and potentially other Pumilio family members-as promising therapeutic targets for mitigating hypoxic pulmonary vascular remodelling.
2. RSV Prevention Products and Severe RSV-Associated Disease Among Infants.
Using a statewide difference-in-differences design across three seasons, the study found no significant reduction in infant RSV-associated hospitalizations/ED visits during 2023–2024, but a 43% relative reduction in 2024–2025 among infants ≤7 months versus older controls. Benefits were generally consistent across racial groups, though attenuated among Native Hawaiian or Other Pacific Islander children.
Impact: Provides robust, quasi-experimental evidence that combined nirsevimab and maternal vaccination programs reduce severe RSV burden at a population level within two seasons.
Clinical Implications: Supports sustained rollout and expanded coverage of infant nirsevimab and maternal RSV vaccination, with attention to equitable access and monitoring of real-world effectiveness across demographics.
Key Findings
- Second season (2024–2025) showed a 43.0% relative reduction in RSV-associated hospitalizations/ED visits among infants ≤7 months beyond trends in 8–24 months (ratio of relative rates).
- No significant reduction in the first season (2023–2024) during limited product availability and uptake.
- Effect sizes were similar across most racial groups, with lower estimated impact among Native Hawaiian or Other Pacific Islander children; median age of cases shifted upward over time.
Methodological Strengths
- Difference-in-differences design with an internal comparison group (8–24 months) to control secular trends
- Use of statewide syndromic surveillance across three seasons with negative binomial modeling
Limitations
- Observational design subject to residual confounding (e.g., care-seeking behavior, testing practices)
- Generalizability limited to a single US state; coverage and access variability may influence results
Future Directions: Evaluate coverage-dependent effectiveness, equity-focused outreach, cost-effectiveness, and combined strategies across jurisdictions; link individual-level exposure and outcomes when feasible.
IMPORTANCE: A long-acting monoclonal antibody (nirsevimab) for use in infants aged 7 months or younger and an antenatal respiratory syncytial virus (RSV) vaccine (RSVpreF) became available in Washington state in 2023. OBJECTIVE: To estimate the combined population-level impact of nirsevimab and antenatal RSV vaccine on the relative rate of RSV-associated hospitalizations and emergency department (ED) visits among infants during the first 2 respiratory seasons of use. DESIGN, SETTING, AND PARTICIPANTS: This difference-in-diferrences cohort study used data from the Washington state syndromic surveillance program on RSV-associated hospitalizations and ED visits among infants from July 1, 2022, to June 30, 2025. EXPOSURE: Introduction of nirsevimab for infants and antenatal RSVpreF. MAIN OUTCOMES AND MEASURES: A difference-in-differences analysis was conducted to estimate mean relative changes in the rate of RSV-associated hospitalizations and ED visits between the period before and the period after introduction of RSV prevention products for children aged 7 months or younger (treatment group) beyond that for children aged 8 to 24 months (comparison group) using negative binomial models. Relative changes were estimated separately for July 1, 2023, to June 30, 2024, and July 1, 2024, to June 30, 2025, vs July 1, 2022, to June 30, 2023.
3. High-Flow Nasal Oxygen Therapy After Cardiac Surgery: A Randomized Clinical Trial.
In 1,280 at-risk adults after nonemergent cardiac surgery, prophylactic HFNOT did not improve the primary outcome of days alive and at home within 90 days compared with standard oxygen therapy. Secondary clinical outcomes were also similar, arguing against routine prophylactic use.
Impact: A large, multicenter RCT with blinded outcome assessment provides definitive evidence to de-implement routine prophylactic HFNOT after cardiac surgery.
Clinical Implications: Routine prophylactic HFNOT after cardiac surgery should not be implemented; focus resources on targeted use or alternative strategies based on individualized risk and signs of respiratory compromise.
Key Findings
- Primary outcome DAH90 was 0 (IQR 0–79) with HFNOT vs 0 (IQR 0–87) with SOT; no difference (P=0.75).
- Secondary outcomes, including DAH90 without the additional support component, were similar between groups.
- Trial included concealed allocation, blinded outcome assessors, and adaptive design across 17 centers in 3 countries.
Methodological Strengths
- Multicenter randomized design with concealed allocation and blinded outcome assessors
- Preplanned sample size re-estimation and pragmatic inclusion criteria targeting high-risk population
Limitations
- Primary outcome (DAH90) may be influenced by non-respiratory factors and health system variations
- Findings pertain to prophylactic use immediately post-extubation; do not exclude benefit in rescue/therapeutic contexts
Future Directions: Identify subgroups who might benefit from HFNOT (e.g., specific phenotypes, weaning failure risk), compare targeted HFNOT vs standard care, and evaluate cost-effectiveness.
IMPORTANCE: High-flow nasal oxygen therapy (HFNOT) is used for noninvasive respiratory support following cardiac surgery despite uncertainty about its clinical effectiveness or associated costs. OBJECTIVE: To determine whether prophylactic HFNOT in patients at increased risk of respiratory complications following cardiac surgery has clinical benefits compared with standard oxygen therapy (SOT). DESIGN, SETTING, AND PARTICIPANTS: This adaptive, parallel group, randomized clinical trial collected and analyzed data from 17 cardiac surgery centers in 3 countries between October 7, 2020, and June 19, 2024. Eligible participants included adults undergoing nonemergent cardiac surgery with any of the following risk factors for pulmonary complications: chronic obstructive pulmonary disease, asthma, lower respiratory tract infection in the last 4 weeks, a body mass index of 35 or greater, or currently or recently smoking for longer than 10 pack-years. Outcome assessors were blinded. A preplanned sample size re-estimation was conducted after 300 participants completed the 90-day follow-up. INTERVENTION: Participants were randomized at a 1:1 ratio with concealed allocation to HFNOT or SOT administered for at least 16 hours immediately after postoperative extubation. MAIN OUTCOMES AND MEASURES: The primary effectiveness outcome was days alive and at home (DAH) without increased support compared with baseline in the first 90 days (DAH90). Any day of increased support, including at home, would provide a value of 0 for that day. Secondary outcomes included DAH90 without considering the additional support component.